Bupropion sustained release
and smoking cessation
by
Goldstein MG
Miriam Hospital and Department of
Psychiatry and Human Behavior,
Brown University School of Medicine,
Providence, RI 02906, USA.
J Clin Psychiatry 1998; 59 Suppl 4:66-72

ABSTRACT

The identification of nicotine dependence as a psychiatric disorder and increased knowledge of nicotine's neuropharmacologic effects have stimulated researchers to search for new pharmacologic interventions for smoking cessation. After reviewing the efficacy and safety of bupropion sustained release (SR) as an agent for treating smoking cessation, the Food and Drug Administration recently approved the use of bupropion SR for this indication. This paper reviews nicotine's pharmacologic effects and the factors contributing to the development of nicotine dependence, the general principles and strategies for treating nicotine dependence, and the evidence for the efficacy of bupropion SR as a treatment for smoking cessation. The release of bupropion SR as a treatment for smoking cessation may provide clinicians with additional opportunities to address smoking cessation with their patients.

Zyban
Tobacco
Bupropion
Varenicline
Bupropion SR
Coffee and fags
Zyban: why worry?
Bupropion and mania
Smoking and depression
Antidepressants: nicotine
Bupropion and depression
Bupropion for nicotine quitters
Bupropion and nicotinic receptors
Can hypericum help tobacco addicts?
Bupropion, noradrenaline and serotonin
Bupropion, amphetamine and cigarettes
Quitting smoking: the role of antidepressants
Bupropion (Zyban): prescribing information (PDF)
Bupropion enhances pleasure for smokers who quit
Zyban/bupropion SR for tobacco smokers in remission

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family